PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 4, 2022Medical Science MonitorOpen Access

A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases

View Full Paper
Ask AI
Bookmark
Share

Why the study?

This review aims to present the roles of ticagrelor in the management of acute coronary syndrome, acute thrombotic disease, and other diseases, focusing on its pharmacological mechanisms and superiority over clopidogrel.

Does ticagrelor improve outcomes in patients with acute coronary syndrome and acute thrombotic disease compared to clopidogrel or aspirin alone?

Design

Review

Authors

LTLuyuan TaoSRShijia RenLZLi Zhang

Discussion

Loading...

Member takes

Overview

Ticagrelor’s pharmacological profile may favor use in ACS; low-certainty evidence leaves open benefits for cardiac output or index.

Key Points

  • To review the pharmacological profile, clinical superiority over clopidogrel, and expanding therapeutic applications of ticagrelor in acute coronary syndrome and other thrombotic diseases.
  • Synthesized mechanistic and clinical evidence from major randomized trials, including the PLATO trial and the phase 3 THALES trial (NCT03354429).
  • Evaluated pharmacodynamics, reversible P2Y12 inhibition kinetics, and pleiotropic cardioprotective properties across cardiovascular and cerebrovascular indications.
  • Ticagrelor achieved faster onset and offset of selective platelet inhibition compared to clopidogrel, resulting in a lower incidence of the primary composite endpoint in the PLATO trial.
  • In the phase 3 THALES trial (NCT03354429), ticagrelor (90 mg) plus aspirin significantly reduced rates of stroke and death compared with aspirin monotherapy in acute ischemic stroke or transient ischemic attack.
  • Beyond antiplatelet aggregation, ticagrelor demonstrated pleiotropic benefits, including improved coronary blood flow, reduced myocardial necrosis post-ischemia, and anti-inflammatory activity.

Structured PICO

Does ticagrelor improve outcomes in patients with acute coronary syndrome and acute thrombotic disease compared to clopidogrel or aspirin alone?

P
Population
Patients with acute coronary syndrome (ACS), acute thrombotic disease, and other diseases
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel or aspirin alone

This review highlights the pharmacological advantages and clinical superiority of ticagrelor over clopidogrel in managing acute coronary syndrome and acute thrombotic diseases.

Cite This Study

Tao et al. (2022) studied this question.

synapsesocial.com/papers/69ecbf6f2fbab654750dcfa3https://doi.org/10.12659/msm.935664
View Full Paper
Ask AI
Bookmark
Share